AMG-1
From Wikipedia, the free encyclopedia
 |
|
|
AMG-1
|
|
| Systematic (IUPAC) name | |
| (6aR,10aR)-3-(hept-1-ynyl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
|
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C23H30O2 |
| Mol. mass | 338.482 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
AMG-1 is an analgesic drug which is a cannabinoid agonist. It is a derivative of Δ8THC with a rigidified and extended 3-position side chain. AMG-1 is a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 0.6nM at CB1 vs 3.1nM at CB2.[1]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
[edit] References
- ^ Papahatjis DP, Nikas SP, Kourouli T, Chari R, Xu W, Pertwee RG, Makriyannis A. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. Journal of Medicinal Chemistry. 2003 Jul 17;46(15):3221-9. PMID 12852753
|
|||||||||||||||||||||||||||||||||||||
